Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lykos Therapeutics
AddedFeb 17, 2024
UpdatedJun 18, 2026
Lykos Therapeutics

Lykos Therapeutics

Series A

Lykos Therapeutics: Revolutionizing mental health with innovative, science-backed psychedelic therapies.

HQ
San Jose, CA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize mental health treatment, Lykos Therapeutics focuses on developing innovative, science-backed psychedelic therapies. The company aims to upend traditional mental health care by creating and marketing novel medicines and therapeutic techniques, particularly for disorders like PTSD. With over thirty years of expertise in psychedelic-assisted therapies, Lykos Therapeutics is committed to rigorous scientific research to ensure the efficacy and safety of its treatments.

Lykos Therapeutics has garnered attention for its groundbreaking work in MDMA-assisted therapy and other psychedelic treatments. The organization boasts a team of seasoned experts and has attracted significant interest from investors focused on mental health innovation. Key achievements include advancing clinical trials and publishing influential research that underscores the potential of psychedelics in mental health care. The overall impact of Lykos Therapeutics lies in its potential to make mental healthcare more accessible and effective for those suffering from severe mental health disorders.

Lykos Therapeutics - Similar Companies

Reset Pharmaceuticals logo

Reset Pharmaceuticals

Woven Science logo

Woven Science

woven.science

Psy Therapeutics logo

Psy Therapeutics

psythx.com

Lysosomal Therapeutics logo

Lysosomal Therapeutics

lysosomaltx.com

Lusaris Therapeutics logo

Lusaris Therapeutics

lusaristx.com

Mimosa Therapeutics logo

Mimosa Therapeutics

Resilience Therapeutics logo

Resilience Therapeutics

Delix Therapeutics logo

Delix Therapeutics

Journey Colab logo

Journey Colab

journeycolab.com

Freedom Biosciences logo

Freedom Biosciences

freedombio.co

Seelos Therapeutics logo

Seelos Therapeutics

Mindstate Design Labs logo

Mindstate Design Labs

mindstate.design

Sensorium Therapeutics logo

Sensorium Therapeutics

sensorium.bio

Gilgamesh Pharmaceuticals logo

Gilgamesh Pharmaceuticals

Hyka logo

Hyka

hyka.io

Lykos Therapeutics - Quick Facts

Who are Lykos Therapeutics' competitors?

Companies similar to Lykos Therapeutics include Reset Pharmaceuticals, Woven Science, Psy Therapeutics and Lysosomal Therapeutics.

When was Lykos Therapeutics founded?

Lykos Therapeutics was founded in 2014.

Where is Lykos Therapeutics' headquarters located?

Lykos Therapeutics' headquarters is located in San Jose, CA, US.

When was Lykos Therapeutics' last funding round?

Lykos Therapeutics' most recent funding round was for $100M (USD) in January 2024.

How much has Lykos Therapeutics raised to-date?

As of Jan 5, 2024, Lykos Therapeutics has raised a total of $100M (USD).

How many employees does Lykos Therapeutics have?

Lykos Therapeutics has 175 employees as of Feb 4, 2024.

Lykos Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Biotech
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified